While the link between diabetes and periodontal disease is known, the impact of diabetes treatment on periodontal health is less well understood.
FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu
Share this article In the DESTINY-PanTumor02 trial, subjects treated with Daiichi Sankyo-AstraZeneca’s Enhertu achieved a confirmed ORR of 51.4%. Credit: Anna in Sweden / Shutterstock.com.